Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711716 | 1.00 | MEN1 (0.48) | MEN1KMT2AALDH1A1CASP3PKM | |
| SCHEMBL3203712 | 0.87 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1CASP3PKM | |
| SCHEMBL22279598 | 0.85 | TRPC5 (0.46) | MEN1KMT2AALDH1A1CASP3PKM | |
| SCHEMBL7020611 | 0.82 | CCKBR (0.53) | MEN1KMT2AHPGDTSHR | |
| SCHEMBL4920256 | 0.82 | CCKBR (0.53) | MEN1KMT2AHPGDTSHR | |
| SCHEMBL13177349 | 0.78 | USP30 (0.62) | ALDH1A1L3MBTL1ATMUSP30MAPK1 | |
| SCHEMBL853540 | 0.78 | USP30 (0.62) | ALDH1A1L3MBTL1ATMUSP30MAPK1 | |
| SCHEMBL14037432 | 0.78 | USP30 (0.62) | ALDH1A1L3MBTL1ATMUSP30MAPK1 | |
| SCHEMBL1055082 | 0.78 | USP30 (0.62) | ALDH1A1L3MBTL1ATMUSP30MAPK1 | |
| SCHEMBL853539 | 0.78 | USP30 (0.62) | ALDH1A1L3MBTL1ATMUSP30MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183019-B2 | (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine or (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine; enzyme-catalysed enantioselective hydrolysis of a racemic 3,4-trans-disubstituted pyrrolidinone; for purine nucleoside phosphorylase (PNP) inhibitors | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-22 | — | — | US | disclosed |
| US-8183019-B2 | (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine or (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine; enzyme-catalysed enantioselective hydrolysis of a racemic 3,4-trans-disubstituted pyrrolidinone; for purine nucleoside phosphorylase (PNP) inhibitors | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-22 | — | — | US | disclosed |
| EP-1756052-B1 | IMPROVED METHOD FOR PREPARING 3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDINE COMPOUNDS | IND RES LTD (NZ) | 2008-12-10 | — | — | EP | disclosed |
| US-20080280334-A1 | Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2008-11-13 | — | — | US | disclosed |
| US-20080280334-A1 | Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280334-A1 | Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds | HPD, DHPS, CYP3A5 | MEN1 3068/4885KMT2A 1957/4885ALDH1A1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.